Tag: meeting

Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

SALT LAKE CITY, Oct. 14, 2020 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will present results from studies suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men as well as the safety and efficacy of TLANDO™, an oral testosterone replacement therapy without a dose titration requirement, at the 21st Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (“SMSNA”). Lipocine will outline the possible mechanisms and clinical evidence that suggests men with low testosterone have poor COVID-19 outcomes, and the rationale of using an oral testosterone therapy for men with COVID-19. Results from the previously completed dose validation (“DV”) study of a fixed dose TLANDO in hypogonadal males will also be presented at the meeting.  The presentations will take place virtually on November 9, 2020 from 7:00 p.m.9:00 p.m. EST during Session 2 (Androgens and Ejaculation/Orgasm Disorders). 

https://www.smsna.org/V1/2020/program/scientific-program?where_person=44
https://www.smsna.org/V1/2020/program/scientific-program?where_person=42

“We know that while COVID-19 infection rates are comparable between men and women, men are developing severe symptoms and dying at a significant higher rate than women. Furthermore, men with comorbidities commonly associated with lower testosterone are at greater risk for severe disease and death,” said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine Inc.  “The presentation on COVID-19 highlight key clinical evidences suggesting that low testosterone levels may play an important role on the clinical outcomes of COVID-19 in men. Based on the published data, the use of oral testosterone with the goal of achieving physiological testosterone levels should be evaluated in clinical trials of COVID-19.”

Dr. Anthony DelConte, Chief Medical Director of Lipocine further stated, “TLANDO will be the first oral testosterone for treatment hypogonadism without titration requirement. It is expected to be easy to prescribe and use.” Dr. DelConte added, “The SMSNA presentation on TLANDO highlights the key safety and efficacy data from multiple clinical studies supporting TLANDO’s ability to effectively restore testosterone levels in hypogonadal men without need for any dose adjustment.”

Is Oral Testosterone a Potential Treatment for COVID-19 in Men? (Benjamin J. Bruno et al)

The authors performed a literature search to understand the possible mechanisms and clinical evidence concerning testosterone levels in COVID-19 patients.  A recent clinical study investigating testosterone levels in men with COVID-19 found 80% of men who died due to COVID-19 had low total or bioavailable testosterone levels at the time of hospital admission. Those with severe Acute Respiratory Distress Syndrome (“ARDS”) had acutely depressed total testosterone compared to patients who did not exhibit severe ARDS. The mean total testosterone levels for men who required invasive ventilation was 29 ng/dL (normal range ~300-1100 ng/dL), whereas those who were discharged from the ICU had mean total T of 254 ng/dL at the time of ICU admission.

In comparison to other routes of testosterone administration, oral testosterone therapy may be the most convenient and suitable for acute treatment of COVID-19 in

Continue reading

Japan firms fall woefully short of meeting government goals on women in management – Reuters poll

TOKYO (Reuters) – About one-fifth of Japanese companies have no female managers and most say women account for less than 10% of management, a Reuters monthly poll found, highlighting the struggle for the government’s “womenomics” drive to make headway.

FILE PHOTO: A woman wearing a protective face mask uses an escalator in a quiet business district on the first working day after the Golden Week holiday, following the coronavirus disease (COVID-19) outbreak, in Tokyo, Japan, May 7,2020.REUTERS/Kim Kyung-Hoon

The survey results come as Japan is seen to delay its target this year to raise the share of women in leadership posts to 30% as part of the government’s campaign to empower women, dubbed “womenomics”, and cope with Japan’s ageing population.

The Reuters Corporate Survey, conducted Sept. 29-Oct. 8, found 71% of Japanese firms said women accounted for less than 10% of management, while 17% had no female managers at all.

Asked how much scope there was to increase female managers, 55% said by around 10%, a quarter said by about 20%, one in 10 firms said by around 30%, while 5% saw no room for that.

“Regardless of sex, we should hire talented people and promote them on their merits, rather than putting priority on the proportion,” a chemicals maker manager wrote in the survey.

A paper and pulp maker manager wrote: “We hire more female new graduates than male, but many female hires tend to leave the company after a while, making it hard to raise female managers.”

The survey, conducted for Reuters by Nikkei Research, canvassed 485 large and midsize non-financial firms. About 240 firms answered the questions on condition of anonymity.

The results were similar to the previous poll taken in 2018.

Japan’s global ranking on gender parity fell to 121st out of 153 countries in a World Economic Forum report for 2020.

New premier Yoshihide Suga’s 21-member cabinet has just two female ministers, and women account for just short of 10% of all lawmakers in parliament’s powerful lower house.

While aiming to follow his predecessor Shinzo Abe’s policies including the coronavirus pandemic response, Suga has pledged to allow insurance coverage for expensive fertility treatments.

On the pandemic impact on employment and wages, 47% of Japan firms suffered it, causing many to curb new hiring, slash wages and reduce staff, the survey showed.

One third of firms expect employment to remain short of pre-pandemic levels at the year end, while a slim majority, 52% of firms, saw capital expenditure would undershoot their initial plans, dampening prospects for sustained economic recovery.

Reporting by Tetsushi Kajimoto; Editing by Muralikumar Anantharaman

Source Article

Continue reading

Japan firms fall woefully short of meeting government goals on women in management: Reuters poll

By Tetsushi Kajimoto

TOKYO (Reuters) – About one-fifth of Japanese companies have no female managers and most say women account for less than 10% of management, a Reuters monthly poll found, highlighting the struggle for the government’s “womenomics” drive to make headway.

The survey results come as Japan is seen to delay its target this year to raise the share of women in leadership posts to 30% as part of the government’s campaign to empower women, dubbed “womenomics”, and cope with Japan’s ageing population.

The Reuters Corporate Survey, conducted Sept. 29-Oct. 8, found 71% of Japanese firms said women accounted for less than 10% of management, while 17% had no female managers at all.

Asked how much scope there was to increase female managers, 55% said by around 10%, a quarter said by about 20%, one in 10 firms said by around 30%, while 5% saw no room for that.

“Regardless of sex, we should hire talented people and promote them on their merits, rather than putting priority on the proportion,” a chemicals maker manager wrote in the survey.

A paper and pulp maker manager wrote: “We hire more female new graduates than male, but many female hires tend to leave the company after a while, making it hard to raise female managers.”

The survey, conducted for Reuters by Nikkei Research, canvassed 485 large and midsize non-financial firms. About 240 firms answered the questions on condition of anonymity.

The results were similar to the previous poll taken in 2018.

Japan’s global ranking on gender parity fell to 121st out of 153 countries in a World Economic Forum report for 2020.

New premier Yoshihide Suga’s 21-member cabinet has just two female ministers, and women account for just short of 10% of all lawmakers in parliament’s powerful lower house.

While aiming to follow his predecessor Shinzo Abe’s policies including the coronavirus pandemic response, Suga has pledged to allow insurance coverage for expensive fertility treatments.

On the pandemic impact on employment and wages, 47% of Japan firms suffered it, causing many to curb new hiring, slash wages and reduce staff, the survey showed.

One third of firms expect employment to remain short of pre-pandemic levels at the year end, while a slim majority, 52% of firms, saw capital expenditure would undershoot their initial plans, dampening prospects for sustained economic recovery.

(Reporting by Tetsushi Kajimoto; Editing by Muralikumar Anantharaman)

Source Article

Continue reading

Lake George board, superintendent violated open meeting law, judge rules

LAKE GEORGE – A ruling from a state Supreme Court justice determined the central school district’s superintendent and board of education violated an open meetings law, but did not give Lake George United for Education what they wanted — their assistant principal back.

Justice Thomas Nolan’s Sept. 30 decision concluded that the breach of the open meetings law doesn’t void or reverse the board’s March 2018 resolution to remove Assistant Principal Cody Conley in favor of hiring a curriculum coordinator.

“The topic that was discussed was one permitted to be discussed in executive session,” Nolan wrote in his decision. “This does not evince, in this court’s judgment, either conscious or malicious or deliberate effort by the Board to violate the law or that the Board has engaged in a documented, persistent pattern of such violations.”

The decision, as first reported by the Post-Star of Glens Falls, the judge declined to award legal fees to LGUE, a community group that filed the Article 78 lawsuit against the school board and Superintendent Lynne Rutnik.

The decision did not satisfy Patricia Dow, the lead petitioner on the LGUE lawsuit.


“While LGUE is disappointed that the Supreme Court was unwilling to impose any consequences on the superintendent and board of education for depriving the public of its statutory right to observed the regular business of the board, we are grateful that the court agreed that the law was violated,” Dow said in a written statement.

Dow said that the board and superintendent misled the public when they announced their executive session was held to discuss an employee’s history, not a position elimination and Nolan agreed.

However, in her statement, Dow also said that the superintendent didn’t consult the district’s professional staff  before deciding to eliminate Conley’s position, showing the superintendent was “unwilling to collaborate with district professionals on how best to deliver critically needed services to our students.”

Rutnik has said the reason for not consulting staff was because the decision “was too difficult to make with a great deal of objectivity.”

Even though Dow didn’t get everything that the suit was meant to achieve, LGUE has won over voters. All of the 2018 board member are gone. One of the last, Tom Seguljic, lost his bid for re-election this year.

The board is now packed with members of LGUE including Jeannine Beiber, who husband was a petitioner on the suit against the district, and Melissa Seale who was an original petitioner. (She dropped her name from the suit at some point.) Also on the board from LGUE are President Tricia Connor Biles, Katie Bruenig, Maryanne MacKenzie and Rosemarie Earl. The only person on the board who is independent of LGUE is Lin King whose term ends in 2022.

Rutnik did not return a Times Union phone call to discuss how the LGUE-led board could affect her employment with the district when her contract expires 2024. She did release a statement, however.

“This decision presents an opportunity for the LGCSD board of education and

Continue reading

Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.


DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020


“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.


DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.


“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr. Farberg. “Based on the cohort described in a recent meta-analysis by Greenhaw and colleagues, we modeled the use of Castle’s DecisionDx-Melanoma test to determine whether it might alter the predictive value of SLNB alone in high-risk patients, and whether the test might identify patients who would not benefit from SLNB. In fact, we found that use of the test stratifies risk in the cohort studied, which can help focus the resources needed for SLNB on patients with genuinely higher risk, thereby reducing surgical risks for patients who can avoid SLNB.”


Study methods and findings:


  • The study objective was to model the use of DecisionDx-Melanoma to triage cutaneous melanoma patients for SLNB, to evaluate the outcomes of low-risk patients who can forgo SLNB and to evaluate the combined accuracy of DecisionDx-Melanoma and SLNB in high-risk patients.

  • The model was based on use of DecisionDx-Melanoma to triage the patients from the recently published systematic review and meta-analysis (Greenhaw et al. JAAD, Sept., 2020), assuming that:

    • Patients with a Class 1A result who were 55 years of age or older with T1-T2 melanoma would not undergo SLNB;

    • The negative predictive value of DecisionDx-Melanoma for recurrence-free survival, distant metastasis free survival and ultimately melanoma specific survival would be high for patients who would not have undergone SLNB due to DecisionDx-Melanoma triage; and

    • The remaining patients would undergo SLNB.

  • Result showed that:

    • 69% of all patients could forgo an SLNB due to a DecisionDx-Melanoma Class 1A test result, and the negative predictive value for 5-year melanoma specific survival was 98%.

    • For the remaining 31% of patients who would undergo an SLNB:

      • Sensitivity for melanoma specific death was 87% for DecisionDx-Melanoma compared with 73% for SLNB. Combining DecisionDx-Melanoma with SLNB improved sensitivity to 96%.

      • Negative predictive value for melanoma specific death was 95% for DecisionDx-Melanoma, compared with 94% for SLNB. Combining DecisionDx-Melanoma with SLNB improved negative predictive value to 98%.

  • The study concluded that use of DecisionDx-Melanoma to triage patients with
Continue reading

KAHR Announces Oral Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

JERUSALEM, Oct. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that an abstract reporting preclinical data for DSP107, a second generation CD47x41BB targeting compound for the treatment of solid tumors and hematological malignancies, has been accepted for an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually from December 5-8, 2020.

“The ASH Annual Meeting will be an important opportunity to present mechanistic studies and extensive in vitro and in vivo results from our novel CD47x41BB clinical stage drug candidate,” said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. “We look forward to advancing the clinical development of this novel therapy.”

The following abstract will be posted on the ASH website on November 5, 2020, at 9:00 a.m. ET:

Title: DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses

Publication Number: 173
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Session Date: Saturday, December 5, 2020
Session Time: 12:00 PM – 1:30 PM
Presentation Time: 12:30 PM

Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Approaches to Overcome Resistance

About DSP107

DSP107 targets CD47-overexpressing tumors, simultaneously blocking macrophage inhibitory signals and delivering an immune costimulatory signal to tumor antigen-specific, activated T-cells.  CD47 is overexpressed on many cancer cells and binds SIRPα on immune phagocytic cells to produce a “don’t eat me” signal.  DSP107 binds CD47 on cancer cells, blocking interaction with SIRPα and thus, blocking the “don’t eat me signal”. Simultaneously, DSP107 binds 41BB on T-cells, stimulating their activation. These activities lead to targeted immune activation through both macrophage and T-cell mediated tumor destruction. 

About DPS107 Phase I/II

A Phase I/II clinical trial to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of DSP107 as a monotherapy and in combination with Roche’s PD-L1-blocking checkpoint inhibitor (CPI) atezolizumab (Tecentriq®) in patients with advanced solid tumors is currently being activated. The preliminary efficacy of both DSP107 monotherapy and combination therapy with atezolizumab will also be evaluated in patients with advanced non-small-cell lung carcinoma (NSCLC) who progressed after treatment with PD-1/PD-L1 inhibitors. The study will be conducted at multiple centers in the United States under a clinical collaboration with Roche.

About KAHR

KAHR develops the next generation of immuno-oncology drug candidates for the treatment of multiple types of cancer. The Company’s lead product, DSP107, is a second generation CD47x41BB targeting compound that simultaneously targets cancer cells, weakens their innate defenses and activates an effective, local response of both innate and adaptive immunity. KAHR’s technology platform is based on multi-functional immuno-recruitment proteins (MIRP) that utilize overexpression of checkpoint antigens on cancer cells in order to selectively target and bind to the tumor. MIRPs binding cancer cells to immune cells to produce a targeted synergistic effect by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting

Continue reading

Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

Oral presentations include:

  • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
  • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
  • Presenter: Joely Kaufman, MD
  • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general

    Continue reading

    Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting | Nachricht

    IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ –Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

    The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

    Oral presentations include:

    • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
    • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
    • Presenter: Joely Kaufman, MD
    • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general muscle weakness,

    Continue reading

    Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery’s Annual Meeting (ASDS)

    DUBLIN, Oct. 9, 2020 /PRNewswire/ — Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics’ Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured during the American Society for Dermatologic Surgery’s Annual Meeting (ASDS). These data will be highlighted in three posters and two oral presentations during the virtual meeting taking place October 9 – 11, 2020.

    Oral Presentations

    On Friday, October 9th a presentation titled “Results From a 1000+ Subject Survey Assessing Satisfaction With a Hypothetical 1-Point Improvement on the Validated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) Analysis,” will be given by Sabrina Fabi, M.D., a board-certified dermatologist in California. Dr. Fabi will share results from a study designed to determine if a 1-point improvement in PR-PCSS score is a clinically meaningful outcome and will highlight the importance of patient education during consultations.

    On Sunday, October 11th, Melanie Palm, M.D., will present “Real-World Effectiveness and Safety of Collagenase Clostridium Histolyticum-aaes Injections for the Treatment of Thigh Cellulite in Women: An Interim Analysis”. During this presentation, Dr. Palm, a board-certified dermatologist and cosmetic surgeon in California, will outline the 90-day findings from ongoing phase 3b REAL™ and PIXELS™ studies assessing not only investigator-perceived and patient-reported results at 90-days, but also the quantitative corroboration of these findings, with 3D-image scans.

    Poster Presentations

    All poster presentations will be available for ASDS attendees throughout the Congress.

    • Title: Long-Term Durability of Collagenase Clostridium Histolyticum-aaes Treatment Effectiveness for Cellulite in Women
    • Authors: Joely Janette Kaufman, M.D., Vernon Leroy Young, M.D., Matthew Zook, M.D., Saji Vijayan, MBBS, D.Diab., Michael McLane PhD., Xiang Q Ph.D., Chajko KA, Lawrence Bass, M.D.
       
  • Title: Patient Retention Strategies for Long-Term Extension Aesthetic Studies: Collagenase Clostridium Histolyticum-aaes (QWO™) Phase 3 Clinical Study Experience
    • Authors: Joely Janette Kaufman, M.D., James Clark M.D., Kappa Peddy, M.D., Alex Cazzaniga Ph.D., Davina Cupo, Robert Yon, Rosalie Filling
       
  • Title: A Survey of Dermatology Healthcare Professional Knowledge, Perception, and Experience Regarding Cellulite and Its Treatment
    • Authors: Jill Edgecombe, Daniel Connolly, Sherry Chen, Stephanie Wenstrup

    “We are pleased with the breadth and depth of the data that will be presented at the ASDS meeting,” said Matthew Davis, M.D., R.Ph., Senior Vice President and Chief Medical Officer of Endo. “Endo Aesthetics is committed to offering aesthetic healthcare providers data not only on the safety and efficacy of QWO, but also on the real world implications of this treatment, including patient retention and perceptions, as we prepare for the product’s launch in spring 2021.”

    INDICATION
    QWO is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

    IMPORTANT SAFETY INFORMATION FOR QWO CONTRAINDICATIONS
    QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Serious hypersensitivity

    Continue reading

    Castle Biosciences to Present Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

    Oral presentations to highlight both commercially available skin cancer prognostic tests

    Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data will be featured in oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, October 9-11, 2020.

    Presentation details are as follows:

    Title: Clinical validation and incorporation of a prognostic 40-gene expression profile test into clinicopathological risk assessment for cutaneous squamous cell carcinoma (cSCC)
    Session: Skin Cancer & Reconstruction
    Presenter: Sherrif Ibrahim M.D., Ph.D., associate professor, University of Rochester Medical Center
    Date: Friday, October 9, 2020
    Time: 6:24 p.m. – 6:27 p.m. ET

    Title: Cutaneous melanoma prognostic model combining 31-gene expression profile and sentinel lymph node biopsy
    Session: Skin Cancer & Reconstruction
    Presenter: Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas
    Date: Friday, October 9, 2020
    Time: 6:30 p.m. – 6:33 p.m. ET

    The virtual presentations will be available to meeting registrants for 30 days following the meeting.

    About DecisionDx-Melanoma

    DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors, and has been studied in more than 5,700 patient samples. Using tissue from the primary melanoma, the test measures the expression of 31 genes. The test has been validated in four archival risk of recurrence studies of 901 patients and six prospective risk of recurrence studies including more than 1,600 patients. Prediction of the likelihood of sentinel lymph node positivity has also been validated in two prospective multicenter studies that included more than 3,000 patients. Impact on patient management plans for one of every two patients tested has been demonstrated in four multicenter and single-center studies including more than 560 patients. The consistent performance and accuracy demonstrated in these studies provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results. Through June 30, 2020, DecisionDx-Melanoma has been ordered more than 59,900 times for use in patients with cutaneous melanoma.

    About DecisionDx-SCC

    DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management.

    Peer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.

    More information about the test and disease can be found at www.mySCCskincancer.com.

    About Castle Biosciences

    Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma, DecisionDx®-CMSeq

    Continue reading